drugset / Trial / NCT04319276
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Timeline
- Start
- 2022-11-11
- Primary completion
- 2025-02-13
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gallium maltolate | Small molecule | 500 mg | Oral |
| Subject | Gallium maltolate | Small molecule | 1000 mg | Oral |
| Subject | Gallium maltolate | Small molecule | 1500 mg | Oral |
| Subject | Gallium maltolate | Small molecule | 2000 mg | Oral |
| Subject | Gallium maltolate | Small molecule | 2500 mg | Oral |